{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:45:00Z","timestamp":1648964700710},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Center for Human Reproduction","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Foundation for Reproductive Medicine","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previously anecdotally observed rebounds in follicle growth after interruption of exogenous gonadotropins in absolute non-responders were the impetus for here reported study. In a prospective cohort study, we investigated 49 consecutive patients, absolutely unresponsive to maximal exogenous gonadotropin stimulation, for a so-called rebound response to ovarian stimulation. A rebound response was defined as follicle growth following complete withdrawal of exogenous gonadotropin stimulation after complete failure to respond to maximal gonadotropin stimulation over up to 5\u20137\u00a0days. Median age of study patients was 40.5\u2009\u00b1\u20095.1\u00a0years (range 23\u201352). Women with and without rebound did not differ significantly (40.0\u2009\u00b1\u20096.0 vs. 41.0\u2009\u00b1\u20097.0 years, <jats:italic>P<\/jats:italic>\u2009=\u20090.41), with 24 (49.0%) recording a rebound and 25 (51.0%) not. Among the former, 21 (87.5%) reached retrieval of 1\u20133 oocytes and 15 (30.6%) reached embryo transfer. A successful rebound in almost half of prior non-responders was an unsuspected response rate, as was retrieval of 1\u20133 oocytes in over half of rebounding patients. Attempting rebounds may, thus, represent another incremental step in very poor prognosis patients before giving up on utilization of autologous oocytes. Here presented findings support further investigations into the underlying physiology leading to such an unexpectedly high rebound rate.<\/jats:p>","DOI":"10.1186\/s13048-021-00765-5","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T18:06:50Z","timestamp":1610215610000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rate of rebound in follicle growth after cessation of ovarian stimulation in initial non\u2010responders: a prospective cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Norbert","family":"Gleicher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Weghofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah K.","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Barad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"765_CR1","doi-asserted-by":"crossref","unstructured":"Albertini DF, Barad DH, Darmon S, Gleicher N, Kushnir VA. Older women using their own eggs? Issue framed with two oldest reported IVF pregnancies and a live birth. Reprod Biomed Online. 2018 Aug;37(2):172\u20137.","DOI":"10.1016\/j.rbmo.2018.05.010"},{"issue":"6","key":"765_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/01.AOG.0000264065.37661.a0","volume":"109","author":"DH Barad","year":"2007","unstructured":"Barad DH, Gleicher N, Weghofer A. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol. 2007;109(6):1404\u201310.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"765_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.rbmo.2010.12.002","volume":"22","author":"DH Barad","year":"2011","unstructured":"Barad DH, Gleicher N, Weghofer A. Utility of age-specific serum anti-M\u00fcllerian. hormone concentrations Reprod Biomed Online. 2011;22(3):284\u201391.","journal-title":"hormone concentrations Reprod Biomed Online"},{"issue":"1","key":"765_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13048-018-0398-8","volume":"11","author":"DF Albertini","year":"2018","unstructured":"Albertini DF, Barad DH, Darmon SK, Gleicher N, Kushnir VA, Wang Q, Zhang L, Wu YG. With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization. J Ovarian Res. 2018;11(1):23.","journal-title":"J Ovarian Res."},{"key":"765_CR5","doi-asserted-by":"crossref","unstructured":"Albertini DF, Barad DH, Darmon SK, Gleicher N, Kushnir VA, Sen A, Wang Q, Weghofer A, Wu YG, Zhang L. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med. 2016 Jun;10(1):172. 14(.","DOI":"10.1186\/s12967-016-0924-7"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s10815-020-01847-x","volume":"37","author":"EY Adashi","year":"2020","unstructured":"Adashi EY, Barad DH, Gleicher N. Why is use of donor eggs not viewed as treatment failure? A call for improvements in treatment with autologous oocytes. J Assist Reprod Genet. 2020;37:1583\u20138.","journal-title":"J Assist Reprod Genet"},{"key":"765_CR7","doi-asserted-by":"crossref","unstructured":"Yding Andersen C. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online 202;5(3):232\u2013239.","DOI":"10.1016\/S1472-6483(10)61826-3"},{"issue":"4","key":"765_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/03009734.2017.1412373","volume":"122","author":"K Eriksson","year":"2017","unstructured":"Eriksson K, Wide L. Molecular size and charge as dimensions to identify and characterize circulating glycoforms of human FSH, LH and TSH. Ups J Med Sci. 2017;122(4):217\u201323.","journal-title":"Ups J Med Sci"},{"issue":"2","key":"765_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/03009734.2018.1467983","volume":"123","author":"K Eriksson","year":"2018","unstructured":"Eriksson K, Wide L. Low-glycosylated forms of both FSH and LH play major roles in the natural ovarian stimulation. Ups J Med. 2018;123(2):100\u20138.","journal-title":"Ups J Med"},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.mce.2015.01.026","volume":"405","author":"VY Butnev","year":"2015","unstructured":"Butnev VY, Butnev VY, May JV, Shuai B, Tran P, White WK, Brown A, Smalter Hall A, Harvey DJ, Bousfied GR. Production, purification, and characterization of recombinant hFSH glycoforms for functional studies. Mol Cell Endocrinol. 2015;405:42\u201351.","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"765_CR11","first-page":"E852-60","volume":"100","author":"GR Bousfield","year":"2015","unstructured":"Bousfield GR, Butnev VY, Davis JS, Jiang C, Hou X, May JV, Wang C. Hypoglycosilated hFSH has greater bioactivity than fully glycosylated recombinant hFSH in human granulosa cells. J Clin Endocrinol Metab. 2015;100(6):E852-60.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"765_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12958-016-0167-8","volume":"14","author":"DB Seifer","year":"2016","unstructured":"Seifer DB, Orvieto R. Biosimilar FSH preparations- are they identical twins or just siblings? Reprod Biol Endocrinol. 2016;14(1):32.","journal-title":"Reprod Biol Endocrinol"},{"key":"765_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3389\/fendo.2019.00503","volume":"10","author":"L Aguzzoli","year":"2019","unstructured":"Aguzzoli L, Casarini L, Daolio J, De Pascali F, Galano E, Klett D, Lazzaretti C, Limoncella S, Nicoli A, Palmese Am Satwekar A, Paradiso E, Poti F, Reiter E, Riccetti L, Simoni M, Sperduti S, Tagliavini S, Trenti T, Villani MT. Glycosylation pattern and in vitro bioactivity of reference follitropin alfa and biosimilars. Frontiers Endocrinol. 2019;10:503.","journal-title":"Frontiers Endocrinol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00765-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-021-00765-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00765-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T18:25:48Z","timestamp":1610216748000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00765-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00765-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As rebounds has been routinely utilized at CHR for years, this study did not change clinical practice. Since data analyses, in addition, were performed using the CHR\u2019s anonymized electronic research data base, this study was approved by the center\u2019s IRB based on expedited review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Author\u2019s own rights to all of the data contained in the manuscript and give permission for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.G., and D.H.B. are listed as co-owners of a number of already awarded and still pending U.S. patents, some claiming benefits from androgen supplementation in women with low ovarian reserve, a topic peripherally addressed in this manuscript. N.G. is a shareholder in Fertility Nutraceuticals, LLC, which produces a DHEA product, and is owner of The CHR. N.G. and D.H.B. receive patent royalties from Fertility Nutraceuticals, LLC. N.G., and D.H.B also received research support, travel funding and lecture fees from various Pharma and medical device companies, none, in any way related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}